The U.S. Food and Drug Administration has granted full approval to sparsentan, marketed as Filspari, for the reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The decision marks a significant milestone in nephrology, as the FDA approves Filspari for focal segmental glomerulosclerosis as the first and only medication specifically approved to treat this rare kidney disorder.
FSGS is a challenging condition characterized by the scarring of the glomeruli—the tiny filtering units of the kidney. When these filters are damaged, they leak protein into the urine, a process known as proteinuria. If left unchecked, this leakage can accelerate the decline of kidney function, eventually leading to end-stage renal disease and the need for dialysis or a transplant. Until now, clinicians have largely relied on off-label use of blood pressure medications and immunosuppressants to manage the disease.
The approval expands the utility of sparsentan, which previously received FDA authorization in 2024 for the treatment of immunoglobulin A (IgA) nephropathy. By extending the indication to include both adults and children, the therapy provides a targeted option for a patient population that has long lacked a dedicated pharmaceutical intervention.
Clinical Evidence from the DUPLEX Trial
The FDA’s decision was informed by the results of the phase 3 DUPLEX trial, which compared the efficacy of sparsentan against irbesartan, a commonly used angiotensin II receptor blocker. The trial focused on the drug’s ability to reduce proteinuria and slow the decline of the estimated glomerular filtration rate (eGFR), a primary indicator of overall kidney health.
Across the overall study population, patients treated with sparsentan achieved a 46% reduction in proteinuria from baseline to week 108, compared to a 30% reduction in those receiving the maximum dose of irbesartan. The results were even more pronounced in the subgroup of patients without nephrotic syndrome, who saw a 48% reduction in proteinuria versus 27% in the irbesartan group.
Beyond the reduction of protein leakage, the trial indicated a positive trend in preserving kidney function. In patients without nephrotic syndrome, those taking sparsentan experienced a slower decline in eGFR (–11.3 mL/min/1.73 m²) compared to the irbesartan group (–12.4 mL/min/1.73 m²). While the numerical difference in eGFR decline is modest, in the context of chronic kidney disease, any slowing of function loss can potentially delay the progression toward kidney failure.
| Metric | Sparsentan | Irbesartan |
|---|---|---|
| Overall Proteinuria Reduction | 46% | 30% |
| Proteinuria Reduction (Non-Nephrotic) | 48% | 27% |
| eGFR Decline (Non-Nephrotic) | –11.3 mL/min/1.73 m² | –12.4 mL/min/1.73 m² |
A Dual-Action Approach to Kidney Protection
From a pharmacological perspective, sparsentan is a first-in-class dual endothelin-angiotensin II receptor antagonist. Most traditional kidney medications target only one pathway—usually the renin-angiotensin-aldosterone system (RAAS)—to lower blood pressure and reduce protein leakage. Yet, endothelin-1, a potent vasoconstrictor, also plays a critical role in promoting inflammation and fibrosis (scarring) within the kidney.
By simultaneously blocking both the endothelin A (ETA) receptor and the angiotensin II type 1 (AT1) receptor, sparsentan addresses two distinct drivers of kidney damage. This dual mechanism is designed to reduce the pressure within the glomeruli and limit the progression of the scarring that defines FSGS, offering a more comprehensive approach than single-receptor blockers.
Safety Profile and Patient Considerations
The DUPLEX trial indicated that sparsentan was generally well tolerated, with a safety profile similar to that of irbesartan. However, given that the drug affects blood pressure and potassium levels, careful monitoring is required. The most common adverse reactions reported include:
- Peripheral edema: Swelling in the extremities.
- Hypotension: Low blood pressure, including orthostatic hypotension (a drop in blood pressure upon standing).
- Hyperkalemia: Elevated levels of potassium in the blood, which can be dangerous if not monitored.
- Other effects: Dizziness and anemia.
the current approval specifically applies to patients without nephrotic syndrome. Nephrotic syndrome is a more severe manifestation of kidney disease characterized by extreme proteinuria, low serum albumin, and significant edema. Patients with this syndrome may have different treatment requirements and risk profiles, and the current data does not extend this approval to that specific subgroup.
Eric Dube, PhD, president and CEO of Travere Therapeutics, noted that the medication will be available for nephrologists to prescribe immediately, filling a void for patients who have previously had few approved options.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a licensed healthcare provider or nephrologist to determine if this treatment is appropriate for their specific medical condition.
As the medical community integrates Filspari into standard care for FSGS, the next critical checkpoints will be real-world evidence studies to determine the drug’s long-term impact on kidney survival and potential expanded trials for patients with nephrotic syndrome. Official prescribing guidelines from nephrology associations are expected to be updated as more clinical experience with the drug accumulates.
Do you have questions about recent kidney disease treatments? Share your thoughts or experiences in the comments below.
